Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,290 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07587684RecruitingPhase 1
Testing IN026 for Hard-to-Treat Gout
This study tests a new drug called IN026 for people with refractory gout—gout that doesn't respond well to current treatments and causes severe symptoms. The goal is to see if IN026 can lower uric acid levels and reduce gout attacks.
WuhanAges 18–75 - NCT07593859Recruiting
Brain Stimulation Research Study for Healthy Adults
This study tests a new non-invasive brain stimulation technique called transcranial temporal interference stimulation. Researchers want to understand how to make it work better and safer in humans.
Boston, MassachusettsAges 18–65 - NCT07588022Recruiting
How Your Body Reacts to Jägermeister Mixed with Energy Drinks
This study examines what happens to your heart, blood pressure, and overall health when you drink Jägermeister (a digestif liqueur) mixed with energy drinks. Researchers want to understand the physical effects of combining alcohol and high-caffeine beverages in healthy young adults.
BarcelonaAges 18–45 - NCT07584876RecruitingPhase 1
Safety study of a new blood clotting medicine in healthy adults
This is an early-stage safety study testing a new experimental medicine that affects blood clotting in people with no serious health conditions. Researchers want to make sure the medicine is safe and well-tolerated before testing it in patients who need it.
Perth, Western AustraliaAges 18–65 - NCT07582432RecruitingPhase 3
Gamunex for Blood Cancer Patients With Low Antibodies
This trial tests whether Gamunex, an antibody replacement therapy, helps patients with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma who have low immunoglobulin (antibody) levels. The treatment may reduce infections and improve how well the body fights disease.
St. Petersburg, FloridaAges 18 years+ - NCT07577856RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe ulcerative colitis
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
Anaheim, CaliforniaAges 18 years+ - NCT07581431RecruitingPhase 1
Testing ISM8969 in healthy and obese adults with heart disease risk
This early-stage trial tests a new drug called ISM8969 to see if it's safe and how the body handles it. Participants are either healthy adults or adults who are overweight with risk factors for heart disease, like high blood pressure or high cholesterol.
Melbourne, VictoriaAges 18–80 - NCT07581210RecruitingPhase 2
QD202 Study for Recent Stroke Treated With Clot-Busting Medicine
This study tests whether a new drug called QD202 can help protect the brain and improve recovery when given alongside standard clot-busting therapy (thrombolysis) for acute ischemic stroke. You would be in the trial if you had a stroke in the last 24 hours and are receiving or planning to receive thrombolytic treatment.
Meizhou, GuangdongAges 18–85 - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Duarte, CaliforniaAges 18 years+ - NCT07585266RecruitingPhase 3
New drug velzatinib versus imatinib for untreated GIST
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
Scottsdale, ArizonaAges 18 years+ - NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Anaheim, CaliforniaAges 18 years+ - NCT07580586RecruitingPhase 1
Study of BV100's effect on polymyxin B in healthy volunteers
This early-stage study tests how a new drug called BV100 affects how your body processes polymyxin B, an antibiotic. Researchers want to understand how these two drugs interact so they can develop safer treatments.
ViennaAges 18–55 - NCT07582783Recruiting
Treatment Persistence with Guselkumab for Moderate-to-Severe Plaque Psoriasis
This study tracks how well patients stick with guselkumab, a biologic injection medication for moderate-to-severe plaque psoriasis. Researchers want to understand real-world treatment outcomes in Romania to help improve psoriasis care.
BârladAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT07584265Recruiting
Understanding Factor V Leiden and Prothrombin Mutations
This study helps researchers learn more about two inherited blood-clotting conditions: Factor V Leiden and Prothrombin G20210A mutations. By participating, you'll help doctors better understand these conditions and how they affect people's health.
LondonAges 18 years+ - NCT05943249Recruiting
MRI technique study using healthy adult volunteers
This is a study that tests new ways to use MRI (a body scan that uses magnets) using healthy volunteers. It helps researchers improve scanning methods, which may make future scans safer or clearer.
LondonAges 18 years+ - NCT06019455Recruiting
How patients participate in lung and esophageal cancer care
This study looks at how much patients with lung or esophageal cancer get involved in decisions about their care when they receive chemotherapy and radiation together. It aims to learn what helps or challenges patients in taking an active role.
GuangzhouAges 18–75 - NCT06725524RecruitingPhase 1
New drug for B-cell lymphoma that returned after treatment
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
ShanghaiAges 18–70 - NCT07571161RecruitingPhase 3
Donanemab for early Alzheimer's disease in Chinese participants
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
BeijingAges 55–80 - NCT07568678RecruitingPhase 1
Testing HMS1005 in adults with type 2 diabetes
This study tests a new medicine called HMS1005 in people with type 2 diabetes. Researchers want to see how safe it is and how the body responds to different doses. You may qualify if you have type 2 diabetes that is either untreated or controlled with common diabetes medications.
Miami, FloridaAges 18–65 - NCT07570862RecruitingPhase 2
CAR T-Cell Therapy for Hard-to-Treat Lupus Kidney Disease
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Beverly Hills, CaliforniaAges 12–70 - NCT07573631Enrolling by invitationPhase 2
Long-term Safety Study of BMN 351 for Duchenne Muscular Dystrophy
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
Milan, ItalyAges 4 years+ - NCT07570147RecruitingPhase 1
Safety study of ABBV-1451 infusions and injections in healthy adults
This early-stage trial tests how the body handles a new experimental drug called ABBV-1451, given as either an infusion (IV drip) or injection. Researchers want to make sure it's safe and well-tolerated in healthy volunteers before testing it in people with medical conditions.
Grayslake, IllinoisAges 18–60 - NCT07571746RecruitingPhase 2
Surovatamig for antibody-mediated kidney disease
This study tests a new medicine called surovatamig for adults with a specific type of kidney disease caused by the body's own antibodies (anti-PLA2R antibody-positive membranous nephropathy). The medicine may help reduce kidney damage and improve kidney function.
Los Angeles, CaliforniaAges 18–75
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,290 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.